Steady Progress against HER2-Positive Breast Cancer

被引：7
|
作者：
Hayes, Daniel F. [1 ]
机构：
[1] Univ Michigan, Breast Oncol Program, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2011年 / 365卷 / 14期
关键词：
ADJUVANT TRASTUZUMAB; DOXORUBICIN; PACLITAXEL; HER2;
D O I：
10.1056/NEJMe1101326
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1336 / 1338
页数：3
相关论文
共 50 条
  • [41] Neratinib (Nerlynx) for HER2-Positive Breast Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2018, 60 (1539): : 23 - 23
  • [42] What is a HER2-positive in breast cancer in 2018?
    Schnitt, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [43] Mutational characterization of HER2-positive breast cancer
    Velasco Sanchez, A.
    Gasol Cudos, A.
    Morales, S.
    Veas Rodriguez, J.
    Serrate Lopez, A.
    Mele Olive, J.
    Canosa Morales, C.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] Targeted Therapy in HER2-Positive Breast Cancer
    Thill, Marc
    Kraft, Clayton
    Friedrich, Michael
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (05) : 295 - 302
  • [45] Personalized Medicine in HER2-positive breast cancer
    Tsurutani, Junji
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] Advances in targeting HER2-positive breast cancer
    Harbeck, Nadia
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2018, 30 (01) : 55 - 59
  • [47] Margetuximab in HER2-positive metastatic breast cancer
    Gradishar, William J.
    O'Regan, Ruth
    Rimawi, Mothaffar F.
    Nordstrom, Jeffrey L.
    Rosales, Minori K.
    Rugo, Hope S.
    FUTURE ONCOLOGY, 2023, 19 (16) : 1099 - 1112
  • [48] Pyrotinib as a therapeutic for HER2-positive breast cancer
    Kioutchoukova, Ivelina
    Lucke-Wold, Brandon P.
    TRANSLATIONAL CANCER RESEARCH, 2023, 12 (06) : 1376 - 1379
  • [49] The Adjuvant Treatment of HER2-Positive Breast Cancer
    Jelovac, Danijela
    Wolff, Antonio C.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2012, 13 (02) : 230 - 239
  • [50] Treatment strategy for HER2-positive breast cancer
    Hirofumi Mukai
    International Journal of Clinical Oncology, 2010, 15 : 335 - 340
12345